Open AccessImmunogenicity and protectivity of the peptide candidate vaccine against SARS-CoV-2
Author(s) -
Alexander B. Ryzhikov,
Evgenii А. Ryzhikov,
M. P. Bogryantseva,
Е. Д. Даниленко,
И.Р. Иматдинов,
Е. А. Нечаева,
Oleg V. Pyankov,
Olga G. Pyankova,
Ivan M. Susloparov,
Oleg S. Taranov,
Andrey S. Gudymo,
N. V. Danilchenko,
Ekaterina S. Sleptsova,
С. А. Боднев,
Galina Onkhonova,
V. N. Petrov,
Anastasiya A. Moiseeva,
P. Yu. Torzhkova,
S. A. Pyankov,
Т. В. Трегубчак,
Денис Антонец,
Elena V. Gavrilova,
Р. А. Максютов
Publication year - 2021
Publication title -
vestnik rossijskoj akademii medicinskih nauk
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.122
H-Index - 15
eISSN - 2414-3545
pISSN - 0869-6047
DOI - 10.15690/vramn1528
Subject(s) - immunogenicity , virology , vaccination , medicine , peptide vaccine , antibody , virus , pneumonia , immunology , biology , epitope
Background: In 2020, the pandemic caused by novel coronavirus infection has become one of the most critical global health challenges during the past century. The lack of a vaccine, as the most effective way to control the novel infection, has prompted the development of a large number of preventive products by the scientific community. We have developed a candidate vaccine (EpiVacCorona) against novel coronavirus infection caused by SARS-CoV-2 that is based on chemically synthesized peptides conjugated to a carrier protein and adsorbed on aluminum hydroxide and studied the specific activity of the developed vaccine.
Aims: Study of the immunogenicity and protectivity of the peptide candidate vaccine EpiVacCorona.
Materials and methods: the work was performed using standard molecular biological, virological and histological methods.
Results: It was demonstrated that EpiVacCorona, when administered twice, spaced 14 days apart, to hamsters, ferrets, and non-human primates (African green monkeys, rhesus macaques) at a dose of 260 g, which is equal to one inoculation dose for humans, induces virus-specific antibodies in 100% of the animals. Experiments in hamsters showed this vaccine to be associated with the dose-dependent immunogenicity. The vaccine was shown to accelerate the elimination of the virus from the upper respiratory tract in ferrets and prevent the development of pneumonia in hamsters and non-human primates following a respiratory challenge with novel coronavirus.
Conclusions: The results of a preclinical specific activity study indicate that the use of EpiVacCorona has the potential for human vaccination.